Healthcare
Fortrea Holdings Inc.(FTRE)
Live Price
Offline$15.56
+1.63% today
1Y Change
+199.23%
Window
Jun 26, 2025 โ Jun 22, 2026
- Market Cap
- $1.46B
- Revenue Growth
- +1.0%
- EPS Growth
- -194.6%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 26, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Fortrea Holdings Inc. (FTRE) is a Healthcare stock with a market cap of $1.46B and listed on NASDAQ. The stock last traded around $15.56 and up 199.2% across the available one-year price window (Jun 26, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +1.0%, EPS growth of -194.6%, a dividend yield of 0.0%. What stands out right now is revenue +1.0%, EPS -194.6%, free cash flow -62.8% with operating margin -0.7% and ROIC -1.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines FTRE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+1.0% vs +7.6% peer median
Operating Margin
Below sector median
-0.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +1.0% and EPS is at -194.6%, with operating margin around -0.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -7.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | -2.5% | -9.3% | +12.6% |
2026 Feb 26, 2026 | -43.8% | -0.7% | -8.1% | -11.6% |
2025 Nov 5, 2025 | -25.0% | -7.8% | -5.1% | +21.3% |
Benchmark Edge
FTRE vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
FTRE
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
FTRE Max Drawdown
-51.79%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for FTRE and SPY.
Company Overview
Fortrea Holdings Inc.
NASDAQ Global Select
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
- Leadership
- Anshul Thakral
- IPO Date
- Jun 20, 2023
- Employees
- 15.0k
- Street Address
- 8 Moore Drive
- Mailing
- Durham, NC, 27709
- Region
- Durham, NC, US
- Reporting Currency
- USD
- Investor Line
- (480)-295-7600
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.5
- Price/Book
- 2.7
Growth
- Revenue
- +1.0%
- EPS
- -194.6%
- Free Cash Flow
- -62.8%
Profitability
- Gross Margin
- 12.1%
- Operating Margin
- -0.7%
- Net Margin
- -16.5%
- ROE
- -79.1%
- ROIC
- -1.0%
Balance Sheet
- Debt/Equity
- 0.14
- Current Ratio
- 0.95
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.